Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MCLA-145 |
Synonyms | |
Therapy Description |
MCLA-145 is a bispecific antibody that binds to CD137 (4-1BB) and PD-L1 and simultaneously activates CD137 and inhibits PD-L1 signaling, which potentially relieves immune suppression resulting in reduced tumor growth (Cancer Res 2019;79(13 Suppl):Abstract nr 539). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MCLA-145 | MCLA145|MCLA 145|anti-PD-L1/4-1BB bispecific antibody | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 TNFRSF9 Antibody 32 | MCLA-145 is a bispecific antibody that binds to CD137 (4-1BB) and PD-L1 and simultaneously activates CD137 and inhibits PD-L1 signaling, which potentially relieves immune suppression resulting in reduced tumor growth (Cancer Res 2019;79(13 Suppl):Abstract nr 539). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung cancer | predicted - sensitive | MCLA-145 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, MCLA-145 treatment inhibited tumor growth in a cell line xenograft model of CD274 (PD-L1) and NY-ESO-positive lung cancer that had adoptive transfer of human T-cells expressing NY-ESO specific T-cell receptors (Cancer Res 2019;79(13 Suppl):Abstract nr 539). | detail... |
CD274 positive | Advanced Solid Tumor | predicted - sensitive | MCLA-145 | Phase I | Actionable | In a Phase I trial, MCLA-145 treatment demonstrated safety and activity in patients with CD274 (PD-L1)-positive advanced solid tumors (n=52), resulting in 5 partial responses (1 each in glioblastoma, sarcoma, cervical cancer, anal cancer, and gastric cancer) and a disease control rate of 37% (J Clin Oncol 42, 2024 (suppl 16; abstr 2520); NCT03922204). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03922204 | Phase I | MCLA-145 | A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies | Completed | USA | NLD | ESP | BEL | 0 |